1.
|
Phase: Phase IV Type: Treatment Status: Active Age: 20 to 75 Sponsor: Other Protocol IDs: ONC-2010-19, NCT01203787
|
|
2.
|
Phase: Phase IV Type: Natural history/Epidemiology Status: Approved-not yet active Age: Any age Sponsor: Pharmaceutical / Industry Protocol IDs: 15246, NX0913IN, NCT01353794
|
|
3.
|
Phase: Phase IV Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 2011PTAHCC, NCT01409499
|
|
4.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: INT 80/09, NCT01387503
|
|
5.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 11718, UVACC-ONYX-11718, UVACC-HIC-11860, EUDRACT-2005-0000941-12, BAYER-UVACC-ONYX-11718, NCT00111007
|
|
6.
|
Phase: Phase III Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: MRC-RE05-SORCE, MRC-RE05-SORCE, EUDRACT ID 2006-006079-19, EU-20734, NCT00492258, SORCE, ISRCTN38934710
|
|
7.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000564099, IPC-BAYPAN, INCA-RECF0426, IPC-2005-006, BAYPAN, NCT00541021
|
|
8.
|
Phase: Phase III Type: Treatment Status: Active Age: 16 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 12311, 2007-002604-17, NCT00625378
|
|
9.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E1208, E1208, NCT01004978
|
|
10.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-80802, CALGB 80802, NCT01015833
|
|
11.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: CDR0000666232, FFCD-PRODIGE-11, FFCD-0803, EUDRACT-2009-015785-64, EU-21005, FFCD-PRODIGE 11 – 0803, NCT01075555
|
|
12.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: AHCC06, NCT01135056
|
|
13.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 and over Sponsor: Other Protocol IDs: SILIUS Phase III trial, NCT01214343
|
|
14.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258A2302, 2009-015459-25, NCT01223027
|
|
15.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 12444, 2010-018501-10, NCT01234337
|
|
16.
|
Phase: Phase III Type: Supportive care Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: Esperanz-002, NCT01265810
|
|
17.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CRUK-TACE-2, TACE-2, 07130, UCL-07130, EU-21108, CRUK-HE3005, EUDRACT-2008-005073-36, CRUK-13136, ISRCTN-93375053, CTA-20363/0272/001, BAYER-CRUK-TACE-2, BIOCOM-UK-CRUK-TACE-2, NCT01324076
|
|
18.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Under 30 Sponsor: NCI Protocol IDs: COG-AAML1031, AAML1031, NCT01371981
|
|
19.
|
Phase: Phase III Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: BOOST, EudraCT number 2009-013870-42, NCT01405573
|
|
20.
|
Phase: Phase III Type: Treatment Status: Active Age: 20 to 80 Sponsor: Other Protocol IDs: CROSS-J-RCC, UMIN000003040, NCT01481870
|
|
21.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: P101103, NCT01482442
|
|
22.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TS-103, NCT01556490
|
|
23.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: 16037 / AN 33/11, 2011-004396-36, NCT01613846
|
|
24.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N0572, N0572, NCT00329719
|
|
25.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 90 Sponsor: Other Protocol IDs: 0603, NCT00414388
|